#1 Clinical Trials Search in Europe

Procarbazine Hydrochloride

Procarbazine Hydrochloride, also known as Natulan, is a chemotherapy drug being studied in various clinical trials for its potential in treating different types of cancer, particularly brain tumors and lymphomas. This article explores the ongoing research into Procarbazine Hydrochloride’s effectiveness, safety, and use in combination with other treatments for patients with challenging cancers.

Table of Contents

What is Procarbazine Hydrochloride?

Procarbazine Hydrochloride is a chemotherapy drug used in the treatment of various types of cancer. It’s also known by the brand name Natulan[1]. This medication belongs to a class of drugs called alkylating agents, which work by stopping cancer cells from dividing and growing[2].

What Conditions Does Procarbazine Treat?

Procarbazine is primarily used to treat several types of cancers and tumors, including:

  • Brain and Central Nervous System Tumors: This includes glioblastoma multiforme, astrocytoma, and oligodendroglioma[3][2].
  • Hodgkin’s Lymphoma: Particularly advanced stages of this cancer of the lymphatic system[1].
  • Primary Central Nervous System Lymphoma (PCNSL): A rare type of non-Hodgkin lymphoma that affects the brain and spinal cord[4].

How Does Procarbazine Work?

Procarbazine works by interfering with the DNA of cancer cells. This interference prevents the cells from dividing and multiplying, which ultimately leads to their death. By targeting rapidly dividing cells, procarbazine can help slow or stop the growth of tumors[2].

How is Procarbazine Administered?

Procarbazine is typically given orally in the form of capsules. The dosage and schedule can vary depending on the specific condition being treated and the overall treatment plan. Some common administration methods include:

  • Daily dosing for 5-14 days, followed by a rest period[5].
  • As part of a combination therapy regimen, where it’s taken on specific days along with other medications[4].

It’s crucial to follow your doctor’s instructions precisely when taking procarbazine, as the timing and dosage are critical for its effectiveness.

Procarbazine in Combination Therapies

Procarbazine is often used as part of combination chemotherapy regimens. Some common combinations include:

  • PCV: Procarbazine, Lomustine (CCNU), and Vincristine[6].
  • BEACOPP: Bleomycin, Etoposide, Adriamycin, Cyclophosphamide, Oncovin (Vincristine), Procarbazine, and Prednisone[1].
  • R-MPV: Rituximab, Methotrexate, Procarbazine, and Vincristine[4].

These combination therapies are designed to attack cancer cells in multiple ways, potentially increasing the effectiveness of treatment.

Potential Side Effects

Like all chemotherapy drugs, procarbazine can cause side effects. Some potential side effects include:

  • Nausea and vomiting
  • Fatigue
  • Loss of appetite
  • Lowered blood cell counts, which can increase the risk of infection or bleeding

Your healthcare team will monitor you closely for these and other side effects during treatment[7].

Ongoing Research and Clinical Trials

Procarbazine continues to be studied in various clinical trials to improve its effectiveness and explore new potential uses. Some areas of ongoing research include:

  • Comparing procarbazine-based regimens with newer chemotherapy drugs like temozolomide[6].
  • Investigating the effectiveness of procarbazine in combination with other drugs for recurrent brain tumors[7].
  • Studying procarbazine as part of treatment protocols for newly diagnosed primary central nervous system lymphoma[4].

These ongoing studies aim to refine treatment strategies and potentially improve outcomes for patients with various types of cancer.

Aspect Details
Primary Cancer Types Brain tumors (glioblastoma, malignant gliomas), CNS lymphomas, Hodgkin’s lymphoma
Common Combinations PCV, BEACOPP, with Methotrexate, Thalidomide, Temozolomide
Administration Typically oral, dosing varies by trial and combination
Key Outcomes Measured Overall survival, progression-free survival, response rates, safety profile
Notable Trials Comparison with Temozolomide, combination with Isotretinoin, modified PCV regimens
Quality of Life Considerations Assessed in multiple trials, including cognitive function impact
Ongoing Research Focus Optimal dosing, comparison with newer drugs, effectiveness in recurrent cancers

FAQ

  • What types of cancer is Procarbazine Hydrochloride being studied for? Procarbazine Hydrochloride is being studied primarily for brain tumors (such as glioblastoma multiforme and other malignant gliomas), central nervous system lymphomas, and Hodgkin's lymphoma.
  • How is Procarbazine Hydrochloride typically administered in clinical trials? In most trials, Procarbazine Hydrochloride is given orally, either daily or on specific days as part of a treatment cycle. The dosage and schedule can vary depending on the specific trial and combination of drugs used.
  • What are some common drug combinations that include Procarbazine Hydrochloride? Common combinations include PCV (Procarbazine, CCNU/Lomustine, and Vincristine), BEACOPP (which includes Procarbazine along with other drugs for Hodgkin's lymphoma), and combinations with drugs like Methotrexate, Thalidomide, or Temozolomide.
  • What are researchers trying to determine about Procarbazine Hydrochloride in these trials? Researchers are studying its effectiveness in improving survival rates, time to disease progression, and overall response rates. They're also assessing its safety profile, optimal dosing, and how it compares to or complements other treatments.
  • Are there any specific side effects being monitored in Procarbazine Hydrochloride trials? While side effects can vary, researchers often monitor for hematologic (blood-related) issues, nausea, fatigue, and potential interactions with other medications. Some trials also assess the impact on quality of life and cognitive function.

Ongoing Clinical Trials on Procarbazine Hydrochloride

  • Study on Reducing Side Effects in Advanced Hodgkin Lymphoma Using Brentuximab Vedotin and Drug Combination for Newly Diagnosed Patients

    Not recruiting

    3 1 1 1
    Investigated drugs:
    Austria Denmark Germany The Netherlands Norway Sweden

Glossary

  • Glioblastoma Multiforme: An aggressive type of cancer that occurs in the brain or spinal cord, forming from cells called astrocytes that support nerve cells.
  • Hodgkin's Lymphoma: A type of cancer that affects the lymphatic system, which is part of the body's germ-fighting immune system.
  • BEACOPP: A chemotherapy regimen that includes Bleomycin, Etoposide, Adriamycin, Cyclophosphamide, Oncovin (Vincristine), Procarbazine, and Prednisone.
  • PCV: A chemotherapy combination that includes Procarbazine, CCNU (Lomustine), and Vincristine.
  • Overall Response Rate (ORR): The proportion of patients whose cancer shrinks or disappears after treatment.
  • Progression-Free Survival: The length of time during and after treatment that a patient lives with the disease but it does not get worse.
  • Maximum Tolerated Dose (MTD): The highest dose of a drug or treatment that does not cause unacceptable side effects.
  • Intrathecal: Injection of medication into the fluid-filled space between the thin layers of tissue that cover the brain and spinal cord.
  • MGMT: A gene that produces a DNA repair protein. Its methylation status can affect response to certain chemotherapies.

References

  1. https://clinicaltrials.gov/study/NCT02800447
  2. https://clinicaltrials.gov/study/NCT00004004
  3. https://clinicaltrials.gov/study/NCT00002840
  4. https://clinicaltrials.gov/study/NCT06541665
  5. https://clinicaltrials.gov/study/NCT00003564
  6. https://clinicaltrials.gov/study/NCT00052455
  7. https://clinicaltrials.gov/study/NCT00079092